Freenome

Valuation $1B

About Freenome

Freenome is a biotechnology company with a comprehensive multiomics platform for cancer detection using a routine blood draw.
Headquarters Freenome, South San Francisco
Founded 2014-01-01
Industry Biotechnology, Health Care, Health Diagnostics, Personal Health
Last Funding Type Series Unknown
Valuation 1
Total Funding $1.35 billion dollars
IPO Status Private

Financial

Freenome may be growing as it has successfully raised $254 million for its multiomic-based early cancer detection platform. This significant funding round indicates strong investor confidence and the availability of substantial capital to support the company's operations and research. The investment will likely facilitate further development of their cancer detection technology, which could lead to advancements in the biotechnology and health diagnostics industries.

Freenome announced positive results for its blood-based test for early detection of colorectal cancer, achieving 79.2% sensitivity and 91.5% specificity. Concurrently, the company is reducing its workforce by about 20%, impacting over 100 employees, as part of a restructuring effort. Additionally, Freenome recently secured $254 million in funding, underscoring its ongoing commitment to cancer detection research.
Funding Rounds 9
Number of Lead Investors 8
Total Funding Amount  $1.35 billion dollars
Number of Investors 54

Related Angels

Anne Wojcicki
View profile